14 Nov Introducing Australia’s first QDP-IHC Section
MetaGene and Applied Spectral Imaging (ASI) are proud to offer Australia’s first QDP-IHC Section and support the Menzies Health Institute Queensland in the creation of the country’s first Quantitative Digital Pathology – Immunohistochemistry Section (QDP-IHC). This department will utilise the GenASIs Digital Pathology platform, approved by the Federal Government Therapeutic Goods Administration (TGA) as a Class III IVD Medical Device.
“This signifies a key step in our journey towards widespread adoption of the ASI GenASIs Digital Pathology system for laboratories and patients in Australia,” MetaGene Managing Director Richard Holder said.
“GenASIs provides higher diagnostic confidence and uncompromising result standardisation, replacing previous indicative diagnosis. Having a TGA approved system at the prestigious Menzies Health Institute Queensland means clinical customers, academic pathologists and scientific researchers can now validate operational performance and benefit from a faster and more accurate means of analysis for IHC , FISH and Cytogenetic samples than ever before.
Image source: Menzies Health Institute Queensland